Washington Trust Advisors’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Washington Trust Advisors’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-58	Closed	-$2K	–	943
2022 Q2	$2K	Hold	58	–	–	﹤0.01%	902
2022 Q1	$2K	Hold	58	–	–	﹤0.01%	968
2021 Q4	$2K	Buy	+58	New	+$4.49K	﹤0.01%	973

Other funds holding RETA

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Washington Trust Advisors's RETA Position: Q3 2022 in Review

Washington Trust Advisors sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2022, closing a stake of 58 shares — an estimated $2K sold.

Washington Trust Advisors first reported a position in RETA in Q4 2021 and held it in 3 quarters. The position peaked at $2K in Q2 2022. 159 funds tracked by Wall St. Rank hold RETA as of Q3 2022.

Washington Trust Advisors reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2022 after selling out during the quarter.
Washington Trust Advisors sold 58 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2022, an estimated $2K.
Washington Trust Advisors first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2021 and held it in 3 quarters.
Washington Trust Advisors's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $2K in Q2 2022.
159 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2022.

Based on Washington Trust Advisors's 13F filing for Q3 2022, filed 14 Oct 2022.